Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Translational Stroke Research
Published in: Translational Stroke Research 5/2016

01-10-2016 | Review Article

Critical Role of the Sphingolipid Pathway in Stroke: a Review of Current Utility and Potential Therapeutic Targets

Authors: Na Sun, Richard F. Keep, Ya Hua, Guohua Xi

Published in: Translational Stroke Research | Issue 5/2016

Login to get access

Abstract

Sphingolipids are a series of cell membrane-derived lipids which act as signaling molecules and play a critical role in cell death and survival, proliferation, recognition, and migration. Sphingosine-1-phosphate acts as a key signaling molecule and regulates lymphocyte trafficking, glial cell activation, vasoconstriction, endothelial barrier function, and neuronal death pathways which plays a critical role in numerous neurological conditions. Stroke is a second leading cause of death all over the world and effective therapies are still in great demand, including ischemic stroke and hemorrhagic stroke as well as poststroke repair. Significantly, sphingolipid activities change after stroke and correlate with stroke outcome, which has promoted efforts to testify whether the sphingolipid pathway could be a novel therapeutic target in stroke. The sphingolipid metabolic pathway, the connection between the pathway and stroke, as well as therapeutic interventions to manipulate the pathway to reduce stroke-induced brain injury are discussed in this review.
Literature
1.
Brunkhorst R, Vutukuri R, Pfeilschifter W. Fingolimod for the treatment of neurological diseases-state of play and future perspectives. Front Cell Neurosci. 2014;8:283. PubMed Central PMCID: PMC4162362.PubMedPubMedCentralCrossRef
2.
3.
Obinata H, Hla T. Sphingosine 1-phosphate in coagulation and inflammation. Semin Immunopathol. 2012;34(1):73–91. PubMed Central PMCID: 3237867.PubMedCrossRef
4.
Rivera J, Proia RL, Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol. 2008;8(10):753–63. PubMed Central PMCID: 2600775.PubMedPubMedCentralCrossRef
5.
Aktas O, Kury P, Kieseier B, Hartung HP. Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol. 2010;6(7):373–82.PubMedCrossRef
6.
Levkau B. Sphingosine-1-phosphate in the regulation of vascular tone: a finely tuned integration system of S1P sources, receptors, and vascular responsiveness. Circ Res. 2008;103(3):231–3.PubMedCrossRef
7.
Coussin F, Scott RH, Wise A, Nixon GF. Comparison of sphingosine 1-phosphate-induced intracellular signaling pathways in vascular smooth muscles: differential role in vasoconstriction. Circ Res. 2002;91(2):151–7.PubMedCrossRef
8.
Prager B, Spampinato SF, Ransohoff RM. Sphingosine 1-phosphate signaling at the blood-brain barrier. Trends Mol Med. 2015;21(6):354–63.PubMedCrossRef
9.
Rosen H, Sanna MG, Cahalan SM, Gonzalez-Cabrera PJ. Tipping the gatekeeper: S1P regulation of endothelial barrier function. Trends Immunol. 2007;28(3):102–7.PubMedCrossRef
10.
Cipriani R, Chara JC, Rodriguez-Antiguedad A, Matute C. FTY720 attenuates excitotoxicity and neuroinflammation. J Neuroinflammation. 2015;12:86. PubMed Central PMCID: 4429813.PubMedPubMedCentralCrossRef
11.
Pyszko JA, Strosznajder JB. The key role of sphingosine kinases in the molecular mechanism of neuronal cell survival and death in an experimental model of Parkinson’s disease. Folia neuropathologica/Association of Polish Neuropathologists and Medical Research Centre. Pol Acad Sci. 2014;52(3):260–9.
12.
13.
Hanada K. Co-evolution of sphingomyelin and the ceramide transport protein CERT. Biochim Biophys Acta. 2014;1841(5):704–19.PubMedCrossRef
14.
Nixon GF, Mathieson FA, Hunter I. The multi-functional role of sphingosylphosphorylcholine. Prog Lipid Res. 2008;47(1):62–75.PubMedCrossRef
15.
Kleger A, Liebau S, Lin Q, von Wichert G, Seufferlein T. The impact of bioactive lipids on cardiovascular development. Stem Cells Int. 2011;2011:916180. PubMed Central PMCID: 3159013.PubMedPubMedCentralCrossRef
16.
Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008;9(2):139–50.PubMedCrossRef
17.
Dobrosotskaya IY, Seegmiller AC, Brown MS, Goldstein JL, Rawson RB. Regulation of SREBP processing and membrane lipid production by phospholipids in Drosophila. Science. 2002;296(5569):879–83.PubMedCrossRef
18.
Kawahara A, Nishi T, Hisano Y, Fukui H, Yamaguchi A, Mochizuki N. The sphingolipid transporter spns2 functions in migration of zebrafish myocardial precursors. Science. 2009;323(5913):524–7.PubMedCrossRef
19.
Kluk MJ, Hla T. Signaling of sphingosine-1-phosphate via the S1P/EDG-family of G-protein-coupled receptors. Biochim Biophys Acta. 2002;1582(1–3):72–80.PubMedCrossRef
20.
21.
Kihara A. Synthesis and degradation pathways, functions, and pathology of ceramides and epidermal acylceramides. Prog Lipid Res. 2016;63:50–69.PubMedCrossRef
22.
Borodzicz S, Czarzasta K, Kuch M, Cudnoch-Jedrzejewska A. Sphingolipids in cardiovascular diseases and metabolic disorders. Lipids Health Dis. 2015;14:55. PubMed Central PMCID: PMC4470334.PubMedPubMedCentralCrossRef
23.
Canals D, Roddy P, Hannun YA. Protein phosphatase 1alpha mediates ceramide-induced ERM protein dephosphorylation: a novel mechanism independent of phosphatidylinositol 4, 5-biphosphate (PIP2) and myosin/ERM phosphatase. J Biol Chem. 2012;287(13):10145–55. PubMed Central PMCID: 3323024.PubMedPubMedCentralCrossRef
24.
Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J, et al. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med. 2013;5(1):105–21. PubMed Central PMCID: 3569657.PubMedCrossRef
25.
Fox TE, Houck KL, O’Neill SM, Nagarajan M, Stover TC, Pomianowski PT, et al. Ceramide recruits and activates protein kinase C zeta (PKC zeta) within structured membrane microdomains. J Biol Chem. 2007;282(17):12450–7.PubMedCrossRef
26.
Henry B, Ziobro R, Becker KA, Kolesnick R, Gulbins E. Acid sphingomyelinase. Handb Exp Pharmacol. 2013;215:77–88.PubMedCrossRef
27.
Chen Y, Ginis I, Hallenbeck JM. The protective effect of ceramide in immature rat brain hypoxia-ischemia involves up-regulation of bcl-2 and reduction of TUNEL-positive cells. J Cereb Blood Flow Metab. 2001;21(1):34–40.PubMedCrossRef
28.
Liu J, Ginis I, Spatz M, Hallenbeck JM. Hypoxic preconditioning protects cultured neurons against hypoxic stress via TNF-alpha and ceramide. Am J Physiol Cell Physiol. 2000;278(1):C144–53.PubMed
29.
Zimmermann C, Ginis I, Furuya K, Klimanis D, Ruetzler C, Spatz M, et al. Lipopolysaccharide-induced ischemic tolerance is associated with increased levels of ceramide in brain and in plasma. Brain Res. 2001;895(1–2):59–65.PubMedCrossRef
30.
Pettus BJ, Bielawska A, Subramanian P, Wijesinghe DS, Maceyka M, Leslie CC, et al. Ceramide 1-phosphate is a direct activator of cytosolic phospholipase A2. J Biol Chem. 2004;279(12):11320–6.PubMedCrossRef
31.
Lamour NF, Wijesinghe DS, Mietla JA, Ward KE, Stahelin RV, Chalfant CE. Ceramide kinase regulates the production of tumor necrosis factor alpha (TNFalpha) via inhibition of TNFalpha-converting enzyme. J Biol Chem. 2011;286(50):42808–17. PubMed Central PMCID: 3234830.PubMedPubMedCentralCrossRef
32.
Kurokawa T, Yumiya Y, Fujisawa H, Shirao S, Kashiwagi S, Sato M, et al. Elevated concentrations of sphingosylphosphorylcholine in cerebrospinal fluid after subarachnoid hemorrhage: a possible role as a spasmogen. J Clin Neurosci. 2009;16(8):1064–8.PubMedCrossRef
33.
Kim HJ, Kim H, Han ES, Park SM, Koh JY, Kim KM, et al. Characterizations of sphingosylphosphorylcholine-induced scratching responses in ICR mice using naltrexon, capsaicin, ketotifen and Y-27632. Eur J Pharmacol. 2008;583(1):92–6.PubMedCrossRef
34.
Imokawa G, Takagi Y, Higuchi K, Kondo H, Yada Y. Sphingosylphosphorylcholine is a potent inducer of intercellular adhesion molecule-1 expression in human keratinocytes. J Invest Dermatol. 1999;112(1):91–6.PubMedCrossRef
35.
Okamoto R, Arikawa J, Ishibashi M, Kawashima M, Takagi Y, Imokawa G. Sphingosylphosphorylcholine is upregulated in the stratum corneum of patients with atopic dermatitis. J Lipid Res. 2003;44(1):93–102.PubMedCrossRef
36.
Byun HJ, Kang KJ, Park MK, Lee HJ, Kang JH, Lee EJ, et al. Ethacrynic acid inhibits sphingosylphosphorylcholine-induced keratin 8 phosphorylation and reorganization via transglutaminase-2 inhibition. Biomol Ther. 2013;21(5):338–42. PubMed Central PMCID: 3825196.CrossRef
37.
Shirao S, Fujisawa H, Kudo A, Kurokawa T, Yoneda H, Kunitsugu I, et al. Inhibitory effects of eicosapentaenoic acid on chronic cerebral vasospasm after subarachnoid hemorrhage: possible involvement of a sphingosylphosphorylcholine-rho-kinase pathway. Cerebrovasc Dis. 2008;26(1):30–7.PubMedCrossRef
38.
Wirrig C, Hunter I, Mathieson FA, Nixon GF. Sphingosylphosphorylcholine is a proinflammatory mediator in cerebral arteries. J Cereb Blood Flow Metab. 2011;31(1):212–21. PubMed Central PMCID: 3049485.PubMedCrossRef
39.
Spiegel S, Milstien S. The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol. 2011;11(6):403–15. PubMed Central PMCID: 3368251.PubMedPubMedCentralCrossRef
40.
Salomone S, Yoshimura S, Reuter U, Foley M, Thomas SS, Moskowitz MA, et al. S1P3 receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate. Eur J Pharmacol. 2003;469(1–3):125–34.PubMedCrossRef
41.
Venkataraman K, Lee YM, Michaud J, Thangada S, Ai Y, Bonkovsky HL, et al. Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res. 2008;102(6):669–76. PubMed Central PMCID: 2659392.PubMedPubMedCentralCrossRef
42.
Pham TH, Baluk P, Xu Y, Grigorova I, Bankovich AJ, Pappu R, et al. Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning. J Exp Med. 2010;207(1):17–27. PubMed Central PMCID: 2812554.PubMedPubMedCentralCrossRef
43.
Graeler M, Goetzl EJ. Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic T cells. FASEB J. 2002;16(14):1874–8.PubMedCrossRef
44.
Lai WQ, Wong WS, Leung BP. Sphingosine kinase and sphingosine 1-phosphate in asthma. Biosci Rep. 2011;31(2):145–50.PubMedCrossRef
45.
Jolly PS, Rosenfeldt HM, Milstien S, Spiegel S. The roles of sphingosine-1-phosphate in asthma. Mol Immunol. 2002;38(16–18):1239–45.PubMedCrossRef
46.
Terai K, Soga T, Takahashi M, Kamohara M, Ohno K, Yatsugi S, et al. Edg-8 receptors are preferentially expressed in oligodendrocyte lineage cells of the rat CNS. Neuroscience. 2003;116(4):1053–62.PubMedCrossRef
47.
Jaillard C, Harrison S, Stankoff B, Aigrot MS, Calver AR, Duddy G, et al. Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J Neurosci. 2005;25(6):1459–69.PubMedCrossRef
48.
Lee MJ, Thangada S, Paik JH, Sapkota GP, Ancellin N, Chae SS, et al. Akt-mediated phosphorylation of the G protein-coupled receptor EDG-1 is required for endothelial cell chemotaxis. Mol Cell. 2001;8(3):693–704.PubMedCrossRef
49.
Ryu Y, Takuwa N, Sugimoto N, Sakurada S, Usui S, Okamoto H, et al. Sphingosine-1-phosphate, a platelet-derived lysophospholipid mediator, negatively regulates cellular Rac activity and cell migration in vascular smooth muscle cells. Circ Res. 2002;90(3):325–32.PubMedCrossRef
50.
Sugimoto N, Takuwa N, Okamoto H, Sakurada S, Takuwa Y. Inhibitory and stimulatory regulation of Rac and cell motility by the G12/13-Rho and Gi pathways integrated downstream of a single G protein-coupled sphingosine-1-phosphate receptor isoform. Mol Cell Biol. 2003;23(5):1534–45. PubMed Central PMCID: 151702.PubMedPubMedCentralCrossRef
51.
Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science. 2009;325(5945):1254–7. PubMed Central PMCID: 2850596.PubMedPubMedCentralCrossRef
52.
Alvarez SE, Harikumar KB, Hait NC, Allegood J, Strub GM, Kim EY, et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature. 2010;465(7301):1084–8. PubMed Central PMCID: 2946785.PubMedPubMedCentralCrossRef
53.
Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest. 2000;106(8):951–61. PubMed Central PMCID: 314347.PubMedPubMedCentralCrossRef
54.
Allende ML, Yamashita T, Proia RL. G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. Blood. 2003;102(10):3665–7.PubMedCrossRef
55.
Mizugishi K, Yamashita T, Olivera A, Miller GF, Spiegel S, Proia RL. Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol. 2005;25(24):11113–21. PubMed Central PMCID: 1316977.PubMedPubMedCentralCrossRef
56.
Camerer E, Regard JB, Cornelissen I, Srinivasan Y, Duong DN, Palmer D, et al. Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice. J Clin Invest. 2009;119(7):1871–9. PubMed Central PMCID: 2701879.PubMedPubMedCentral
57.
Kono M, Mi Y, Liu Y, Sasaki T, Allende ML, Wu YP, et al. The sphingosine-1-phosphate receptors S1P1, S1P2, and S1P3 function coordinately during embryonic angiogenesis. J Biol Chem. 2004;279(28):29367–73.PubMedCrossRef
58.
Ishii I, Ye X, Friedman B, Kawamura S, Contos JJ, Kingsbury MA, et al. Marked perinatal lethality and cellular signaling deficits in mice null for the two sphingosine 1-phosphate (S1P) receptors, S1P(2)/LP(B2)/EDG-5 and S1P(3)/LP(B3)/EDG-3. J Biol Chem. 2002;277(28):25152–9.PubMedCrossRef
59.
Ishii I, Friedman B, Ye X, Kawamura S, McGiffert C, Contos JJ, et al. Selective loss of sphingosine 1-phosphate signaling with no obvious phenotypic abnormality in mice lacking its G protein-coupled receptor, LP(B3)/EDG-3. J Biol Chem. 2001;276(36):33697–704.PubMedCrossRef
60.
MacLennan AJ, Carney PR, Zhu WJ, Chaves AH, Garcia J, Grimes JR, et al. An essential role for the H218/AGR16/Edg-5/LP(B2) sphingosine 1-phosphate receptor in neuronal excitability. Eur J Neurosci. 2001;14(2):203–9.PubMedCrossRef
61.
Herr DR, Grillet N, Schwander M, Rivera R, Muller U, Chun J. Sphingosine 1-phosphate (S1P) signaling is required for maintenance of hair cells mainly via activation of S1P2. J Neurosci. 2007;27(6):1474–8.PubMedCrossRef
62.
Kono M, Belyantseva IA, Skoura A, Frolenkov GI, Starost MF, Dreier JL, et al. Deafness and stria vascularis defects in S1P2 receptor-null mice. J Biol Chem. 2007;282(14):10690–6.PubMedCrossRef
63.
Skoura A, Sanchez T, Claffey K, Mandala SM, Proia RL, Hla T. Essential role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the mouse retina. J Clin Invest. 2007;117(9):2506–16. PubMed Central PMCID: 1940238.PubMedPubMedCentralCrossRef
64.
Du W, Takuwa N, Yoshioka K, Okamoto Y, Gonda K, Sugihara K, et al. S1P(2), the G protein-coupled receptor for sphingosine-1-phosphate, negatively regulates tumor angiogenesis and tumor growth in vivo in mice. Cancer Res. 2010;70(2):772–81.PubMedCrossRef
65.
Wang F, Okamoto Y, Inoki I, Yoshioka K, Du W, Qi X, et al. Sphingosine-1-phosphate receptor-2 deficiency leads to inhibition of macrophage proinflammatory activities and atherosclerosis in apoE-deficient mice. J Clin Invest. 2010;120(11):3979–95. PubMed Central PMCID: 2964972.PubMedPubMedCentralCrossRef
66.
Skoura A, Michaud J, Im DS, Thangada S, Xiong Y, Smith JD, et al. Sphingosine-1-phosphate receptor-2 function in myeloid cells regulates vascular inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31(1):81–5. PubMed Central PMCID: 3013369.PubMedCrossRef
67.
Kim GS, Yang L, Zhang G, Zhao H, Selim M, McCullough LD, et al. Critical role of sphingosine-1-phosphate receptor-2 in the disruption of cerebrovascular integrity in experimental stroke. Nat Commun. 2015;6:7893. PubMed Central PMCID: PMC4587559.PubMedPubMedCentralCrossRef
68.
Michaud J, Im DS, Hla T. Inhibitory role of sphingosine 1-phosphate receptor 2 in macrophage recruitment during inflammation. J Immunol. 2010;184(3):1475–83. PubMed Central PMCID: 3068864.PubMedCrossRef
69.
Levkau B, Hermann S, Theilmeier G, van der Giet M, Chun J, Schober O, et al. High-density lipoprotein stimulates myocardial perfusion in vivo. Circulation. 2004;110(21):3355–9.PubMedCrossRef
70.
Theilmeier G, Schmidt C, Herrmann J, Keul P, Schafers M, Herrgott I, et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation. 2006;114(13):1403–9.PubMedCrossRef
71.
Means CK, Xiao CY, Li Z, Zhang T, Omens JH, Ishii I, et al. Sphingosine 1-phosphate S1P2 and S1P3 receptor-mediated Akt activation protects against in vivo myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2007;292(6):H2944–51.PubMedCrossRef
72.
Takuwa N, Ohkura S, Takashima S, Ohtani K, Okamoto Y, Tanaka T, et al. S1P3-mediated cardiac fibrosis in sphingosine kinase 1 transgenic mice involves reactive oxygen species. Cardiovasc Res. 2010;85(3):484–93. PubMed Central PMCID: 2802201.PubMedCrossRef
73.
Walter DH, Rochwalsky U, Reinhold J, Seeger F, Aicher A, Urbich C, et al. Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor. Arterioscler Thromb Vasc Biol. 2007;27(2):275–82.PubMedCrossRef
74.
Walzer T, Chiossone L, Chaix J, Calver A, Carozzo C, Garrigue-Antar L, et al. Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat Immunol. 2007;8(12):1337–44.PubMedCrossRef
75.
Jenne CN, Enders A, Rivera R, Watson SR, Bankovich AJ, Pereira JP, et al. T-bet-dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow. J Exp Med. 2009;206(11):2469–81. PubMed Central PMCID: 2768857.PubMedPubMedCentralCrossRef
76.
Igarashi N, Okada T, Hayashi S, Fujita T, Jahangeer S, Nakamura S. Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J Biol Chem. 2003;278(47):46832–9.PubMedCrossRef
77.
Le Stunff H, Peterson C, Liu H, Milstien S, Spiegel S. Sphingosine-1-phosphate and lipid phosphohydrolases. Biochim Biophys Acta. 2002;1582(1–3):8–17.PubMedCrossRef
78.
Brindley DN, Pilquil C. Lipid phosphate phosphatases and signaling. J Lipid Res. 2009;50(Suppl):S225–30. PubMed Central PMCID: 2674702.PubMedPubMedCentral
79.
80.
Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–29.PubMedCrossRef
81.
Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375(9727):1695–703.PubMedCrossRef
82.
Donnan GA, Davis SM, Parsons MW, Ma H, Dewey HM, Howells DW. How to make better use of thrombolytic therapy in acute ischemic stroke. Nat Rev Neurol. 2011;7(7):400–9.PubMedCrossRef
83.
Seifert HA, Pennypacker KR. Molecular and cellular immune responses to ischemic brain injury. Transl Stroke Res. 2014;5(5):543–53. PubMed Central PMCID: 4125453.PubMedPubMedCentralCrossRef
84.
85.
Hafez S, Coucha M, Bruno A, Fagan SC, Ergul A. Hyperglycemia, acute ischemic stroke, and thrombolytic therapy. Transl Stroke Res. 2014;5(4):442–53. PubMed Central PMCID: 4112106.PubMedPubMedCentralCrossRef
86.
87.
88.
Gan Y, Liu Q, Wu W, Yin JX, Bai XF, Shen R, et al. Ischemic neurons recruit natural killer cells that accelerate brain infarction. Proc Natl Acad Sci U S A. 2014;111(7):2704–9. PubMed Central PMCID: 3932858.PubMedPubMedCentralCrossRef
89.
Li P, Gan Y, Sun BL, Zhang F, Lu B, Gao Y, et al. Adoptive regulatory T-cell therapy protects against cerebral ischemia. Ann Neurol. 2013;74(3):458–71. PubMed Central PMCID: 3748165.PubMedPubMedCentralCrossRef
90.
Liesz A, Suri-Payer E, Veltkamp C, Doerr H, Sommer C, Rivest S, et al. Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat Med. 2009;15(2):192–9.PubMedCrossRef
91.
Monson NL, Ortega SB, Ireland SJ, Meeuwissen AJ, Chen D, Plautz EJ, et al. Repetitive hypoxic preconditioning induces an immunosuppressed B cell phenotype during endogenous protection from stroke. J Neuroinflammation. 2014;11:22. PubMed Central PMCID: 3926678.PubMedPubMedCentralCrossRef
92.
Bodhankar S, Chen Y, Vandenbark AA, Murphy SJ, Offner H. Treatment of experimental stroke with IL-10-producing B-cells reduces infarct size and peripheral and CNS inflammation in wild-type B-cell-sufficient mice. Metab Brain Dis. 2014;29(1):59–73. PubMed Central PMCID: 3944055.PubMedCrossRef
93.
Bodhankar S, Chen Y, Vandenbark AA, Murphy SJ, Offner H. IL-10-producing B-cells limit CNS inflammation and infarct volume in experimental stroke. Metab Brain Dis. 2013;28(3):375–86. PubMed Central PMCID: 3737266.PubMedPubMedCentralCrossRef
94.
Czech B, Pfeilschifter W, Mazaheri-Omrani N, Strobel MA, Kahles T, Neumann-Haefelin T, et al. The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia. Biochem Biophys Res Commun. 2009;389(2):251–6.PubMedCrossRef
95.
Hasegawa Y, Suzuki H, Sozen T, Rolland W, Zhang JH. Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats. Stroke. 2010;41(2):368–74. PubMed Central PMCID: 2811754.PubMedCrossRef
96.
Wei Y, Yemisci M, Kim HH, Yung LM, Shin HK, Hwang SK, et al. Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol. 2011;69(1):119–29. PubMed Central PMCID: 3200194.PubMedCrossRef
97.
Pfeilschifter W, Czech-Zechmeister B, Sujak M, Mirceska A, Koch A, Rami A, et al. Activation of sphingosine kinase 2 is an endogenous protective mechanism in cerebral ischemia. Biochem Biophys Res Commun. 2011;413(2):212–7.PubMedCrossRef
98.
Choi JW, Chun J. Lysophospholipids and their receptors in the central nervous system. Biochim Biophys Acta. 2013;1831(1):20–32. PubMed Central PMCID: 3693945.PubMedCrossRef
99.
Liu J, Zhang C, Tao W, Liu M. Systematic review and meta-analysis of the efficacy of sphingosine-1-phosphate (S1P) receptor agonist FTY720 (fingolimod) in animal models of stroke. Int J Neurosci. 2013;123(3):163–9.PubMedCrossRef
100.
Kraft P, Gob E, Schuhmann MK, Gobel K, Deppermann C, Thielmann I, et al. FTY720 ameliorates acute ischemic stroke in mice by reducing thrombo-inflammation but not by direct neuroprotection. Stroke. 2013;44(11):3202–10.PubMedCrossRef
101.
Hasegawa Y, Suzuki H, Altay O, Rolland W, Zhang JH. Role of the sphingosine metabolism pathway on neurons against experimental cerebral ischemia in rats. Transl Stroke Res. 2013;4(5):524–32. PubMed Central PMCID: 3811943.PubMedCrossRef
102.
Fu Y, Zhang N, Ren L, Yan Y, Sun N, Li YJ, et al. Impact of an immune modulator fingolimod on acute ischemic stroke. Proc Natl Acad Sci U S A. 2014;111(51):18315–20. PubMed Central PMCID: 4280578.PubMedPubMedCentralCrossRef
103.
Lin JJ, Chang T, Cai WK, Zhang Z, Yang YX, Sun C, et al. Post-injury administration of allicin attenuates ischemic brain injury through sphingosine kinase 2: in vivo and in vitro studies. Neurochem Int. 2015;89:92–100.PubMedCrossRef
104.
Zheng S, Wei S, Wang X, Xu Y, Xiao Y, Liu H, et al. Sphingosine kinase 1 mediates neuroinflammation following cerebral ischemia. Exp Neurol. 2015;272:160–9.PubMedCrossRef
105.
Campos F, Qin T, Castillo J, Seo JH, Arai K, Lo EH, et al. Fingolimod reduces hemorrhagic transformation associated with delayed tissue plasminogen activator treatment in a mouse thromboembolic model. Stroke. 2013;44(2):505–11. PubMed Central PMCID: PMC3586809.PubMedPubMedCentralCrossRef
106.
Herr I, Martin-Villalba A, Kurz E, Roncaioli P, Schenkel J, Cifone MG, et al. FK506 prevents stroke-induced generation of ceramide and apoptosis signaling. Brain Res. 1999;826(2):210–9.PubMedCrossRef
107.
Hisaki H, Okazaki T, Kubota M, Nakane M, Fujimaki T, Nakayama H, et al. L-PDMP improves glucosylceramide synthesis and behavior in rats with focal ischemia. Neurol Res. 2008;30(9):979–84.PubMedCrossRef
108.
Noda H, Takeuchi H, Mizuno T, Suzumura A. Fingolimod phosphate promotes the neuroprotective effects of microglia. J Neuroimmunol. 2013;256(1–2):13–8.PubMedCrossRef
109.
Liesz A, Sun L, Zhou W, Schwarting S, Mracsko E, Zorn M, et al. FTY720 reduces post-ischemic brain lymphocyte influx but does not improve outcome in permanent murine cerebral ischemia. PLoS ONE. 2011;6(6):e21312. PubMed Central PMCID: 3119049.PubMedPubMedCentralCrossRef
110.
Zhang J, Yang Y, Sun H, Xing Y. Hemorrhagic transformation after cerebral infarction: current concepts and challenges. Ann Transl Med. 2014;2(8):81. PubMed Central PMCID: 4200641.PubMedPubMedCentral
111.
Luitse MJ, Biessels GJ, Rutten GE, Kappelle LJ. Diabetes, hyperglycaemia, and acute ischaemic stroke. Lancet Neurol. 2012;11(3):261–71.PubMedCrossRef
112.
Zhu Z, Fu Y, Tian D, Sun N, Han W, Chang G, et al. Combination of the immune modulator fingolimod with alteplase in acute ischemic stroke: a pilot trial. Circulation. 2015;132(12):1104–12. PubMed Central PMCID: PMC4580515.PubMedCrossRef
113.
Latour LL, Kang DW, Ezzeddine MA, Chalela JA, Warach S. Early blood-brain barrier disruption in human focal brain ischemia. Ann Neurol. 2004;56(4):468–77.PubMedCrossRef
114.
Caplan LR. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1999;341(16):1240–1.PubMedCrossRef
115.
Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke. 1997;28(11):2109–18.
116.
Cai A, Schlunk F, Bohmann F, Kashefiolasl S, Brunkhorst R, Foerch C, et al. Coadministration of FTY720 and rt-PA in an experimental model of large hemispheric stroke—no influence on functional outcome and blood-brain barrier disruption. Exp Transl Stroke Med. 2013;5(1):11. PubMed Central PMCID: 4029477.PubMedPubMedCentralCrossRef
117.
Keep RF, Hua Y, Xi G. Intracerebral haemorrhage: mechanisms of injury and therapeutic targets. Lancet Neurol. 2012;11(8):720–31. PubMed Central PMCID: Pmc3884550, Epub 2012/06/16. eng.PubMedCrossRef
118.
119.
Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol. 2006;5(1):53–63.PubMedCrossRef
120.
121.
Xiong XY, Yang QW. Rethinking the roles of inflammation in the intracerebral hemorrhage. Transl Stroke Res. 2015;6(5):339–41.PubMedCrossRef
122.
Schlunk F, Greenberg SM. The pathophysiology of intracerebral hemorrhage formation and expansion. Transl Stroke Res. 2015;6(4):257–63.PubMedCrossRef
123.
van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010;9(2):167–76.PubMedCrossRef
124.
Wang J, Dore S. Inflammation after intracerebral hemorrhage. J Cereb Blood Flow Metab. 2007;27(5):894–908. Epub 2006/10/13. eng.PubMed
125.
Selim M, Sheth KN. Perihematoma edema: a potential translational target in intracerebral hemorrhage? Transl Stroke Res. 2015;6(2):104–6. PubMed Central PMCID: 4359064.PubMedPubMedCentralCrossRef
126.
Zhou Y, Wang Y, Wang J, Anne Stetler R, Yang QW. Inflammation in intracerebral hemorrhage: from mechanisms to clinical translation. Prog Neurobiol. 2014;115:25–44.PubMedCrossRef
127.
Qureshi AI, Ali Z, Suri MF, Shuaib A, Baker G, Todd K, et al. Extracellular glutamate and other amino acids in experimental intracerebral hemorrhage: an in vivo microdialysis study. Crit Care Med. 2003;31(5):1482–9.PubMedCrossRef
128.
Lusardi TA, Wolf JA, Putt ME, Smith DH, Meaney DF. Effect of acute calcium influx after mechanical stretch injury in vitro on the viability of hippocampal neurons. J Neurotrauma. 2004;21(1):61–72.PubMedCrossRef
129.
Graham DI, McIntosh TK, Maxwell WL, Nicoll JA. Recent advances in neurotrauma. J Neuropathol Exp Neurol. 2000;59(8):641–51.PubMedCrossRef
130.
Aronowski J, Zhao X. Molecular pathophysiology of cerebral hemorrhage: secondary brain injury. Stroke. 2011;42(6):1781–6. PubMed Central PMCID: PMC3123894.PubMedPubMedCentralCrossRef
131.
Felberg RA, Grotta JC, Shirzadi AL, Strong R, Narayana P, Hill-Felberg SJ, et al. Cell death in experimental intracerebral hemorrhage: the “black hole” model of hemorrhagic damage. Ann Neurol. 2002;51(4):517–24.PubMedCrossRef
132.
Huang FP, Xi G, Keep RF, Hua Y, Nemoianu A, Hoff JT. Brain edema after experimental intracerebral hemorrhage: role of hemoglobin degradation products. J Neurosurg. 2002;96(2):287–93.PubMedCrossRef
133.
Ziai WC. Hematology and inflammatory signaling of intracerebral hemorrhage. Stroke. 2013;44(6 Suppl 1):S74–8.PubMedCrossRef
134.
Gebel Jr JM, Jauch EC, Brott TG, Khoury J, Sauerbeck L, Salisbury S, et al. Natural history of perihematomal edema in patients with hyperacute spontaneous intracerebral hemorrhage. Stroke. 2002;33(11):2631–5.PubMedCrossRef
135.
Butcher KS, Baird T, MacGregor L, Desmond P, Tress B, Davis S. Perihematomal edema in primary intracerebral hemorrhage is plasma derived. Stroke. 2004;35(8):1879–85.PubMedCrossRef
136.
Hatakeyama T, Okauchi M, Hua Y, Keep RF, Xi G. Deferoxamine reduces neuronal death and hematoma lysis after intracerebral hemorrhage in aged rats. Transl Stroke Res. 2013;4(5):546–53. PubMed Central PMCID: 3810989.PubMedCrossRef
137.
Zheng M, Du H, Ni W, Koch LG, Britton SL, Keep RF, et al. Iron-induced necrotic brain cell death in rats with different aerobic capacity. Transl Stroke Res. 2015;6(3):215–23. PubMed Central PMCID: 4425582.PubMedPubMedCentralCrossRef
138.
Cheng Y, Xi G, Jin H, Keep RF, Feng J, Hua Y. Thrombin-induced cerebral hemorrhage: role of protease-activated receptor-1. Transl Stroke Res. 2014;5(4):472–5. PubMed Central PMCID: 3962522.PubMedCrossRef
139.
Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000;407(6801):258–64.PubMedCrossRef
140.
Kitaoka T, Hua Y, Xi G, Hoff JT, Keep RF. Delayed argatroban treatment reduces edema in a rat model of intracerebral hemorrhage. Stroke. 2002;33(12):3012–8.PubMedCrossRef
141.
Sugawara T, Jadhav V, Ayer R, Chen W, Suzuki H, Zhang JH. Thrombin inhibition by argatroban ameliorates early brain injury and improves neurological outcomes after experimental subarachnoid hemorrhage in rats. Stroke. 2009;40(4):1530–2. PubMed Central PMCID: 2743552, Epub 2009/02/21. eng.PubMedPubMedCentralCrossRef
142.
Finigan JH, Dudek SM, Singleton PA, Chiang ET, Jacobson JR, Camp SM, et al. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem. 2005;280(17):17286–93.PubMedCrossRef
143.
Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood. 2005;105(8):3178–84.PubMedCrossRef
144.
Bae JS, Yang L, Manithody C, Rezaie AR. The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood. 2007;110(12):3909–16. PubMed Central PMCID: 2190610.PubMedPubMedCentralCrossRef
145.
Bae JS, Yang L, Rezaie AR. Lipid raft localization regulates the cleavage specificity of protease activated receptor 1 in endothelial cells. J Thromb Haemost. 2008;6(6):954–61.PubMedCrossRef
146.
Feistritzer C, Schuepbach RA, Mosnier LO, Bush LA, Di Cera E, Griffin JH, et al. Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells. J Biol Chem. 2006;281(29):20077–84.PubMedCrossRef
147.
Wang J. Preclinical and clinical research on inflammation after intracerebral hemorrhage. Prog Neurobiol. 2010;92(4):463–77. PubMed Central PMCID: 2991407.PubMedPubMedCentralCrossRef
148.
Zhao H, Garton T, Keep RF, Hua Y, Xi G. Microglia/macrophage polarization after experimental intracerebral hemorrhage. Transl Stroke Res. 2015;6(6):407–9. PubMed Central PMCID: 4628553.PubMedCrossRef
149.
Chen S, Yang Q, Chen G, Zhang JH. An update on inflammation in the acute phase of intracerebral hemorrhage. Transl Stroke Res. 2015;6(1):4–8.PubMedCrossRef
150.
Hammond MD, Ambler WG, Ai Y, Sansing LH. Alpha4 integrin is a regulator of leukocyte recruitment after experimental intracerebral hemorrhage. Stroke. 2014;45(8):2485–7. PubMed Central PMCID: 4129460.PubMedPubMedCentralCrossRef
151.
Hammond MD, Taylor RA, Mullen MT, Ai Y, Aguila HL, Mack M, et al. CCR2+ Ly6C(hi) inflammatory monocyte recruitment exacerbates acute disability following intracerebral hemorrhage. J Neurosci. 2014;34(11):3901–9. PubMed Central PMCID: 3951693.PubMedPubMedCentralCrossRef
152.
153.
Taylor RA, Sansing LH. Microglial responses after ischemic stroke and intracerebral hemorrhage. Clin Dev Immunol. 2013;2013:746068. PubMed Central PMCID: 3810327.PubMedPubMedCentralCrossRef
154.
Shi FD, Ljunggren HG, La Cava A, Van Kaer L. Organ-specific features of natural killer cells. Nat Rev Immunol. 2011;11(10):658–71. PubMed Central PMCID: 3620656.PubMedPubMedCentralCrossRef
155.
Hua Y, Wu J, Keep RF, Nakamura T, Hoff JT, Xi G. Tumor necrosis factor-alpha increases in the brain after intracerebral hemorrhage and thrombin stimulation. Neurosurgery. 2006;58(3):542–50. discussion -50.PubMedCrossRef
156.
Rolland WB, Lekic T, Krafft PR, Hasegawa Y, Altay O, Hartman R, et al. Fingolimod reduces cerebral lymphocyte infiltration in experimental models of rodent intracerebral hemorrhage. Exp Neurol. 2013;241:45–55. PubMed Central PMCID: 3570752.PubMedCrossRef
157.
Lu L, Barfejani AH, Qin T, Dong Q, Ayata C, Waeber C. Fingolimod exerts neuroprotective effects in a mouse model of intracerebral hemorrhage. Brain Res. 2014;1555:89–96.PubMedPubMedCentralCrossRef
158.
Rolland 2nd WB, Manaenko A, Lekic T, Hasegawa Y, Ostrowski R, Tang J, et al. FTY720 is neuroprotective and improves functional outcomes after intracerebral hemorrhage in mice. Acta Neurochir Suppl. 2011;111:213–7. PubMed Central PMCID: 3569072.PubMedPubMedCentralCrossRef
159.
Fu Y, Hao J, Zhang N, Ren L, Sun N, Li YJ, et al. Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study. JAMA Neurol. 2014;71:1092–101.PubMedCrossRef
160.
Gaberel T, Magheru C, Emery E. Management of non-traumatic intraventricular hemorrhage. Neurosurg Rev. 2012;35(4):485–94. discussion 94-5.PubMedCrossRef
161.
Bhattathiri PS, Gregson B, Prasad KS, Mendelow AD, Investigators S. Intraventricular hemorrhage and hydrocephalus after spontaneous intracerebral hemorrhage: results from the STICH trial. Acta Neurochir Suppl. 2006;96:65–8.PubMedCrossRef
162.
Nieuwkamp DJ, de Gans K, Rinkel GJ, Algra A. Treatment and outcome of severe intraventricular extension in patients with subarachnoid or intracerebral hemorrhage: a systematic review of the literature. J Neurol. 2000;247(2):117–21.PubMedCrossRef
163.
Strahle J, Garton HJ, Maher CO, Muraszko KM, Keep RF, Xi G. Mechanisms of hydrocephalus after neonatal and adult intraventricular hemorrhage. Transl Stroke Res. 2012;3 Suppl 1:25–38. PubMed Central PMCID: 3750748.PubMedPubMedCentralCrossRef
164.
van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet. 2007;369(9558):306–18. Epub 2007/01/30. eng.PubMedCrossRef
165.
Fujii M, Yan J, Rolland WB, Soejima Y, Caner B, Zhang JH. Early brain injury, an evolving frontier in subarachnoid hemorrhage research. Transl Stroke Res. 2013;4(4):432–46. PubMed Central PMCID: 3719879.PubMedPubMedCentralCrossRef
166.
Brilstra EH, Rinkel GJ, Algra A, van Gijn J. Rebleeding, secondary ischemia, and timing of operation in patients with subarachnoid hemorrhage. Neurology. 2000;55(11):1656–60.PubMedCrossRef
167.
Macdonald RL. Delayed neurological deterioration after subarachnoid haemorrhage. Nat Rev Neurol. 2014;10(1):44–58.PubMedCrossRef
168.
Solenski NJ, Haley Jr EC, Kassell NF, Kongable G, Germanson T, Truskowski L, et al. Medical complications of aneurysmal subarachnoid hemorrhage: a report of the multicenter, cooperative aneurysm study. Participants of the Multicenter Cooperative Aneurysm Study. Crit Care Med. 1995;23(6):1007–17.PubMedCrossRef
169.
170.
Song J, Li P, Chaudhary N, Gemmete JJ, Thompson BG, Xi G, et al. Correlating cerebral (18)FDG PET-CT patterns with histological analysis during early brain injury in a rat subarachnoid hemorrhage model. Transl Stroke Res. 2015;6(4):290–5.PubMedCrossRef
171.
Vergouwen MD, Vermeulen M, van Gijn J, Rinkel GJ, Wijdicks EF, Muizelaar JP, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke. 2010;41(10):2391–5.PubMedCrossRef
172.
Budohoski KP, Czosnyka M, Kirkpatrick PJ, Smielewski P, Steiner LA, Pickard JD. Clinical relevance of cerebral autoregulation following subarachnoid haemorrhage. Nat Rev Neurol. 2013;9(3):152–63.PubMedCrossRef
173.
Dhar R, Scalfani MT, Blackburn S, Zazulia AR, Videen T, Diringer M. Relationship between angiographic vasospasm and regional hypoperfusion in aneurysmal subarachnoid hemorrhage. Stroke. 2012;43(7):1788–94. PubMed Central PMCID: 3383942.PubMedPubMedCentralCrossRef
174.
Jaeger M, Schuhmann MU, Soehle M, Nagel C, Meixensberger J. Continuous monitoring of cerebrovascular autoregulation after subarachnoid hemorrhage by brain tissue oxygen pressure reactivity and its relation to delayed cerebral infarction. Stroke. 2007;38(3):981–6.PubMedCrossRef
175.
Testai FD, Hillmann M, Amin-Hanjani S, Gorshkova I, Berdyshev E, Gorelick PB, et al. Changes in the cerebrospinal fluid ceramide profile after subarachnoid hemorrhage. Stroke. 2012;43(8):2066–70.PubMedCrossRef
176.
Tosaka M, Okajima F, Hashiba Y, Saito N, Nagano T, Watanabe T, et al. Sphingosine 1-phosphate contracts canine basilar arteries in vitro and in vivo: possible role in pathogenesis of cerebral vasospasm. Stroke. 2001;32(12):2913–9.PubMedCrossRef
177.
Testai FD, Xu HL, Kilkus J, Suryadevara V, Gorshkova I, Berdyshev E, et al. Changes in the metabolism of sphingolipids after subarachnoid hemorrhage. J Neurosci Res. 2015;93(5):796–805. PubMed Central PMCID: 4359096.PubMedPubMedCentralCrossRef
178.
Yagi K, Lidington D, Wan H, Fares JC, Meissner A, Sumiyoshi M, et al. Therapeutically targeting tumor necrosis factor-alpha/sphingosine-1-phosphate signaling corrects myogenic reactivity in subarachnoid hemorrhage. Stroke. 2015;46(8):2260–70.PubMedCrossRef
179.
Tang H, Zhao D, Chen S, Fang M, Wang F, Cui Y, et al. Expression of sphingosine-1-phosphate (S1P) on the cerebral vasospasm after subarachnoid hemorrhage in rabbits. Acta cirurgica brasileira/Sociedade Brasileira para Desenvolvimento Pesquisa em Cirurgia. 2015;30(10):654–9.PubMed
180.
Salomone S, Soydan G, Ip PC, Hopson KM, Waeber C. Vessel-specific role of sphingosine kinase 1 in the vasoconstriction of isolated basilar arteries. Pharmacol Res. 2010;62(6):465–74. PubMed Central PMCID: 2974794.PubMedPubMedCentralCrossRef
181.
Stetler RA, Leak RK, Gan Y, Li P, Zhang F, Hu X, et al. Preconditioning provides neuroprotection in models of CNS disease: paradigms and clinical significance. Prog Neurobiol. 2014;114:58–83. PubMed Central PMCID: 3937258.PubMedCrossRef
182.
183.
Xi G. Clinical translation of cerebral preconditioning. Transl Stroke Res. 2010;1(1):2–3. PubMed PMID: 25053258. Pubmed Central PMCID: 4187220.PubMedCrossRef
184.
Sheng R, Zhang TT, Felice VD, Qin T, Qin ZH, Smith CD, et al. Preconditioning stimuli induce autophagy via sphingosine kinase 2 in mouse cortical neurons. J Biol Chem. 2014;289(30):20845–57. PubMed Central PMCID: 4110292.PubMedPubMedCentralCrossRef
185.
Wacker BK, Perfater JL, Gidday JM. Hypoxic preconditioning induces stroke tolerance in mice via a cascading HIF, sphingosine kinase, and CCL2 signaling pathway. J Neurochem. 2012;123(6):954–62. PubMed Central PMCID: 3514614.PubMedPubMedCentralCrossRef
186.
Zhou Y, Lekic T, Fathali N, Ostrowski RP, Martin RD, Tang J, et al. Isoflurane posttreatment reduces neonatal hypoxic-ischemic brain injury in rats by the sphingosine-1-phosphate/phosphatidylinositol-3-kinase/Akt pathway. Stroke. 2010;41(7):1521–7. PubMed Central PMCID: 2917259.PubMedPubMedCentralCrossRef
187.
Altay O, Hasegawa Y, Sherchan P, Suzuki H, Khatibi NH, Tang J, et al. Isoflurane delays the development of early brain injury after subarachnoid hemorrhage through sphingosine-related pathway activation in mice. Crit Care Med. 2012;40(6):1908–13. PubMed Central PMCID: 3358576.PubMedPubMedCentralCrossRef
188.
Furuya K, Ginis I, Takeda H, Chen Y, Hallenbeck JM. Cell permeable exogenous ceramide reduces infarct size in spontaneously hypertensive rats supporting in vitro studies that have implicated ceramide in induction of tolerance to ischemia. J Cereb Blood Flow Metab. 2001;21(3):226–32.PubMedCrossRef
189.
Wacker BK, Freie AB, Perfater JL, Gidday JM. Junctional protein regulation by sphingosine kinase 2 contributes to blood-brain barrier protection in hypoxic preconditioning-induced cerebral ischemic tolerance. J Cereb Blood Flow Metab. 2012;32(6):1014–23. PubMed Central PMCID: 3367228.PubMedPubMedCentralCrossRef
190.
Wacker BK, Park TS, Gidday JM. Hypoxic preconditioning-induced cerebral ischemic tolerance: role of microvascular sphingosine kinase 2. Stroke. 2009;40(10):3342–8. PubMed Central PMCID: PMC2753710.PubMedPubMedCentralCrossRef
191.
Yung LM, Wei Y, Qin T, Wang Y, Smith CD, Waeber C. Sphingosine kinase 2 mediates cerebral preconditioning and protects the mouse brain against ischemic injury. Stroke. 2012;43(1):199–204. PubMed Central PMCID: 3246529.PubMedCrossRef
192.
Altay O, Suzuki H, Hasegawa Y, Caner B, Krafft PR, Fujii M, et al. Isoflurane attenuates blood-brain barrier disruption in ipsilateral hemisphere after subarachnoid hemorrhage in mice. Stroke. 2012;43(9):2513–6. PubMed Central PMCID: 3429639.PubMedPubMedCentralCrossRef
193.
Deng J, Lei C, Chen Y, Fang Z, Yang Q, Zhang H, et al. Neuroprotective gases—fantasy or reality for clinical use? Prog Neurobiol. 2014;115:210–45.PubMedCrossRef
194.
Iwai M, Sato K, Omori N, Nagano I, Manabe Y, Shoji M, et al. Three steps of neural stem cells development in gerbil dentate gyrus after transient ischemia. J Cereb Blood Flow Metab. 2002;22(4):411–9.PubMedCrossRef
195.
Kimura A, Ohmori T, Kashiwakura Y, Ohkawa R, Madoiwa S, Mimuro J, et al. Antagonism of sphingosine 1-phosphate receptor-2 enhances migration of neural progenitor cells toward an area of brain. Stroke. 2008;39(12):3411–7.PubMedCrossRef
196.
Harada J, Foley M, Moskowitz MA, Waeber C. Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells. J Neurochem. 2004;88(4):1026–39.PubMedCrossRef
197.
Sofroniew MV. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 2009;32(12):638–47. PubMed Central PMCID: 2787735.PubMedPubMedCentralCrossRef
198.
Yamagata K, Tagami M, Torii Y, Takenaga F, Tsumagari S, Itoh S, et al. Sphingosine 1-phosphate induces the production of glial cell line-derived neurotrophic factor and cellular proliferation in astrocytes. Glia. 2003;41(2):199–206.PubMedCrossRef
199.
Deogracias R, Yazdani M, Dekkers MP, Guy J, Ionescu MC, Vogt KE, et al. Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Proc Natl Acad Sci U S A. 2012;109(35):14230–5. PubMed Central PMCID: 3435172.PubMedPubMedCentralCrossRef
200.
Fukumoto K, Mizoguchi H, Takeuchi H, Horiuchi H, Kawanokuchi J, Jin S, et al. Fingolimod increases brain-derived neurotrophic factor levels and ameliorates amyloid beta-induced memory impairment. Behav Brain Res. 2014;268:88–93.PubMedCrossRef
201.
Doi Y, Takeuchi H, Horiuchi H, Hanyu T, Kawanokuchi J, Jin S, et al. Fingolimod phosphate attenuates oligomeric amyloid beta-induced neurotoxicity via increased brain-derived neurotrophic factor expression in neurons. PLoS ONE. 2013;8(4):e61988. PubMed Central PMCID: 3625222.PubMedPubMedCentralCrossRef
202.
Lapchak PA, Zhang JH, Noble-Haeusslein LJ. RIGOR guidelines: escalating STAIR and STEPS for effective translational research. Transl Stroke Res. 2013;4(3):279–85. PubMed Central PMCID: PMC3644408.PubMedCrossRef
203.
Wang MM, Xi G, Keep RF. Should the STAIR criteria be modified for preconditioning studies? Transl Stroke Res. 2013;4(1):3–14. PubMed Central PMCID: PMC3580874.PubMedPubMedCentralCrossRef
Metadata
Title
Critical Role of the Sphingolipid Pathway in Stroke: a Review of Current Utility and Potential Therapeutic Targets
Authors
Na Sun
Richard F. Keep
Ya Hua
Guohua Xi
Publication date
01-10-2016
Publisher
Springer US
Published in
Translational Stroke Research / Issue 5/2016
Print ISSN: 1868-4483
Electronic ISSN: 1868-601X
DOI
https://doi.org/10.1007/s12975-016-0477-3

Other articles of this Issue 5/2016

Translational Stroke Research 5/2016 Go to the issue

SI: Challenges and Controversies in Translational Stroke Research

Stem Cell Therapy and Administration Routes After Stroke

Original Article

Anesthesia in Experimental Stroke Research

Editorial

Challenges and Controversies in Translational Stroke Research - an Introduction

SI: Challenges and Controversies in Translational Stroke Research

Neuroimaging as a Selection Tool and Endpoint in Clinical and Pre-clinical Trials

SI: Challenges and Controversies in Translational Stroke Research

How to Measure Recovery? Revisiting Concepts and Methods for Stroke Studies

SI: Challenges and Controversies in Translational Stroke Research

Rodent Models of Vascular Cognitive Impairment